James Larkin

Royal Marsden NHS Foundation Trust

London

United Kingdom

SCHOLARLY PAPERS

2

DOWNLOADS

45

CITATIONS

0

Scholarly Papers (2)

1.

Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue

CELL-REPORTS-D-19-02201
Number of pages: 53 Posted: 17 Jun 2019
Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Roche Tissue Diagnostics, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Roche Tissue Diagnostics, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Roche Sequencing Solutions, Cancer Institute of Lorraine - Biopathology Service, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Roche Tissue Diagnostics, Royal Marsden Hospital, Royal Marsden Hospital, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, Roche Tissue Diagnostics, Roche Tissue Diagnostics, Roche Tissue Diagnostics, Roche Sequencing Solutions, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Aarhus University Hospital - Department of Molecular Medicine, Aarhus University Hospital - Department of Molecular Medicine, Aarhus University Hospital - Department of Molecular Medicine, Royal Marsden NHS Foundation Trust, University College London - Cancer Research UK Lung Cancer Centre of Excellence, Royal Marsden NHS Foundation Trust, Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory, Roche Tissue Diagnostics and Francis Crick Institute - Cancer Evolution and Genome Instability Laboratory
Downloads 23 (497,943)

Abstract:

Loading...

Tumor Sequencing, Molecular Profiling, Next Generation Sequencing, Cancer Genetics, Cancer Biomarkers

2.

Epacadostat Plus Pembrolizumab versus Placebo Plus Pembrolizumab in Patients with Unresectable or Metastatic Melanoma: Results of the Phase 3, Randomised, Double-Blind Echo-301/Keynote-252 Study

Number of pages: 39 Posted: 05 Feb 2019
The University of Sydney - Melanoma Institute Australia, University Hospital Zurich, Angeles Clinic and Research Institute, University of Chicago - Medical Center, Universidad del Desarrollo - Facultad de Medicina Clínica Alemana, University of Lyon 1, Hospital Clinic of Barcelona, The University of Sydney - Melanoma Institute Australia, Aix-Marseille University, Seoul National University - Seoul National Hospital, N.N. Blokhin Russian Cancer Research Center, Université Paris XI Sud - Gustave Roussy Cancer Campus, Royal Marsden NHS Foundation Trust, Merck & Co., Inc., Incyte Corporation, Incyte Corporation, Merck & Co., Inc. and University of Pennsylvania, Perelman School of Medicine, Abramson Family Cancer Research Institute
Downloads 22 (503,642)

Abstract:

Loading...

melanoma, indoleamine 2,3-dioxygenase, epacadostat, pembrolizumab, immunotherapy